After years of litigation and a series of legal decisions that never really gave either side any clear advantage, the battle over testosterone therapy and the methods used to market it may finally be coming to a close.
Of the nearly 7,000 lawsuits filed by men claiming that their use of testosterone therapy led to dangerous complications including heart attacks, strokes, and blood clots, more than half ...
continue reading...The same judge who previously overturned a $150 million AndroGel verdict has reversed a second verdict in the litigation worth over $140 million.
The case was brought by Tennessee resident Jeffrey Konrad. Konrad alleges that his two-month period of using AbbVie’s AndroGel testosterone replacement product caused him to have a heart attack in 2010. A Chicago jury agreed and awarded him $140,000 in compensatory damages and $140 million punitively in response to ...
continue reading...Testim maker Endo International’s Auxilium unit emerged victorious in the first trial over whether its testosterone therapy drug caused a heart attack in a patient.
The Tennessee plaintiff had been prescribed Testim for what he described as chronic fatigue and had been applying the testosterone gel to himself for over 6 months. In July 2014, he suffered a heart attack and was subsequently hospitalized twice. His recovery since then ...
continue reading...Yet again, a jury sent AbbVie, maker of the popular prescription testosterone drug Androgel, a loud and clear message. A federal jury in Chicago found that AbbVie misrepresented the dangers of using Androgel. And to make sure the drugmaker got their message, it also reached a verdict in excess of $140 million.
This most recent trial is the second bellwether case to be tried in the federal testosterone replacement therapy ...
continue reading...One would think that a verdict of this magnitude would send a very loud, very clear message to Androgel maker AbbVie. Unfortunately, the testosterone therapy maker may actually escape paying on this verdict, calling into question whether the company will still “hear” the jury.
The $150 million testosterone verdict was just issued in the case of an Oregon man whose lawsuit accused AbbVie of hiding the ...
continue reading...The American Association of Clinical Endocrinologists (AACE) and the American College of Endocrinology (ACE) recently issued a joint position statement on the cardiovascular risks of testosterone therapy. In the statement, the two endocrinology groups questioned the FDA’s recommended method for determining whether a patient requires testosterone therapy and call for more research on the health risks posed by Low-T products.
The FDA has indicated that testosterone therapy is approved ...
continue reading...
